Table 2.
Baseline demographic and clinical characteristics stratified by treatment sequence in patients with Crohn’s disease.
| Total (N = 3008) | ADA to IFX (n = 637) | ADA to VDZ (n = 522) | ADA to UST (n = 446) | IFX to ADA (n = 454) | IFX to VDZ (n = 317) | IFX to UST (n = 185) | VDZ to ADA (n = 55) | VDZ to IFX (n = 56) | VDZ to UST (n = 218) | UST to ADA (n = 44) | UST to IFX (n = 27) | UST to VDZ (n = 47) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Demographic | |||||||||||||
| Age, y | 41.9 (15.3) | 40.6 (15.3) | 43.3 (15.2) | 42.0 (14.1) | 39.9 (14.7) | 44.8 (17.4) | 39.5 (15.2) | 44.7 (13.4) | 40.8 (14.8) | 44.2 (15.7) | 40.8 (14.9) | 43.2 (15.5) | 39.3 (15.1) |
| Sex | |||||||||||||
| Female | 58.6 | 58.7 | 62.8 | 57.6 | 54.4 | 56.8 | 57.8 | 61.8 | 58.9 | 64.2 | 52.3 | 48.2 | 57.5 |
| Male | 41.4 | 41.3 | 37.2 | 42.4 | 45.6 | 43.2 | 42.2 | 38.2 | 41.1 | 35.8 | 47.7 | 51.9 | 42.6 |
| Race/ethnicity | |||||||||||||
| Asian | 0.8 | 0.6 | 0.4 | 0.7 | 0.7 | 1.6 | 0.5 | 0.0 | 0.0 | 1.4 | 0.0 | 3.7 | 6.4 |
| Black or African American | 7.2 | 8.0 | 5.8 | 4.3 | 9.7 | 7.9 | 6.5 | 5.5 | 5.4 | 8.3 | 6.8 | 22.2 | 4.3 |
| White or Caucasian | 89.1 | 88.4 | 91.2 | 92.8 | 86.1 | 87.1 | 88.7 | 90.9 | 94.6 | 87.6 | 90.9 | 70.4 | 89.4 |
| Unknown or other | 2.9 | 3.0 | 2.7 | 2.2 | 3.5 | 3.5 | 4.3 | 3.6 | 0.0 | 2.8 | 2.3 | 3.7 | 0.0 |
| Insurance type | |||||||||||||
| Commercial | 62.5 | 60.0 | 66.7 | 66.4 | 58.8 | 56.8 | 62.7 | 61.8 | 71.4 | 61.5 | 68.2 | 55.6 | 80.9 |
| Medicaid | 9.0 | 10.5 | 6.5 | 4.9 | 12.1 | 10.7 | 12.4 | 10.9 | 12.5 | 5.5 | 11.4 | 18.5 | 0.0 |
| Medicare | 7.6 | 7.9 | 7.1 | 4.3 | 5.3 | 12.6 | 7.0 | 5.5 | 3.6 | 15.6 | 2.3 | 7.4 | 8.5 |
| Commercial/Medicaid | 3.3 | 4.7 | 2.7 | 2.0 | 4.4 | 2.5 | 3.2 | 5.5 | 1.8 | 2.8 | 0.0 | 0.0 | 2.1 |
| Commercial/Medicare | 4.1 | 3.6 | 4.0 | 3.8 | 2.9 | 5.7 | 5.4 | 3.6 | 5.4 | 5.1 | 2.3 | 11.1 | 2.1 |
| Commercial/Medicaid/ Medicare |
0.2 | 0.5 | 0.0 | 0.0 | 0.2 | 0.0 | 0.5 | 0.0 | 0.0 | 0.0 | 0.0 | 3.7 | 0.0 |
| Uninsured | 1.1 | 0.6 | 0.4 | 2.2 | 2.2 | 2.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Missing, unknown, or other | 10.9 | 10.8 | 11.3 | 15.7 | 12.1 | 7.3 | 6.0 | 12.7 | 3.6 | 9.2 | 15.9 | 3.7 | 6.4 |
| Clinical characteristics | |||||||||||||
| Conditions in the pre–index perioda | |||||||||||||
| Mental disorder | 25.6 | 26.1 | 27.6 | 22.0 | 23.6 | 27.1 | 27.6 | 16.4 | 30.4 | 29.4 | 25.0 | 18.5 | 23.4 |
| Cardiovascular disease | 23.9 | 24.0 | 22.0 | 22.9 | 21.4 | 28.1 | 23.8 | 25.5 | 21.4 | 29.8 | 22.7 | 11.1 | 29.8 |
| Chronic pulmonary disease | 15.1 | 16.3 | 15.1 | 11.7 | 16.5 | 17.7 | 12.4 | 20.0 | 7.1 | 14.2 | 13.6 | 14.8 | 19.2 |
| Liver disease | 7.0 | 6.0 | 8.1 | 6.1 | 6.8 | 5.4 | 8.1 | 10.9 | 10.7 | 9.2 | 6.8 | 3.7 | 8.5 |
| Diabetes mellitus | 5.9 | 7.5 | 6.7 | 5.8 | 4.9 | 6.6 | 3.2 | 1.8 | 1.8 | 6.0 | 0.0 | 0.0 | 6.4 |
| CCI score | 0.6 (1.1) | 0.5 (1.0) | 0.6 (1.1) | 0.6 (1.1) | 0.5 (1.0) | 0.6 (1.4) | 0.6 (1.1) | 0.8 (1.2) | 0.6 (0.9) | 0.8 (1.3) | 0.8 (1.3) | 0.5 (0.9) | 0.7 (1.3) |
| Body mass index, kg/m2 | 27.1 (6.8) | 27.4 (6.8) | 27.9 (7.1) | 27.4 (6.6) | 26.6 (6.8) | 27.1 (7.0) | 26.3 (6.4) | 26.4 (6.4) | 24.7 (5.5) | 26.3 (6.3) | 25.9 (5.5) | 26.2 (7.5) | 26.5 (7.0) |
| Smoking | 21.0 | 23.4 | 19.7 | 17.5 | 23.8 | 21.5 | 24.3 | 14.6 | 21.4 | 17.0 | 29.6 | 11.1 | 19.2 |
| Disease characteristics | |||||||||||||
| Perianal disease | 4.7 | 4.1 | 2.9 | 3.4 | 6.4 | 4.7 | 10.8 | 0.0 | 3.6 | 6.0 | 4.6 | 0.0 | 8.5 |
| Fistula | 11.6 | 12.1 | 9.2 | 8.7 | 15.0 | 11.0 | 15.1 | 3.6 | 10.7 | 14.7 | 13.6 | 11.1 | 12.8 |
| Abscess | 4.7 | 4.1 | 2.9 | 3.4 | 6.4 | 4.7 | 10.8 | 0.0 | 3.6 | 6.0 | 4.6 | 0.0 | 8.5 |
| Stricture | 0.2 | 0.2 | 0.6 | 0.0 | 0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.5 | 0.0 | 0.0 | 0.0 |
| Disease location | |||||||||||||
| Ileum-colon | 36.7 | 33.8 | 33.1 | 37.2 | 34.1 | 33.8 | 37.3 | 38.2 | 33.9 | 50.9 | 63.6 | 51.9 | 57.5 |
| Colon | 24.3 | 24.7 | 24.5 | 22.4 | 26.0 | 31.2 | 25.4 | 29.1 | 28.6 | 15.1 | 11.4 | 11.1 | 17.0 |
| Ileum | 19.1 | 21.0 | 19.5 | 19.7 | 18.9 | 16.7 | 15.1 | 16.4 | 19.6 | 17.9 | 20.5 | 25.9 | 17.0 |
| Unspecified | 19.9 | 20.6 | 22.8 | 20.6 | 20.9 | 18.3 | 22.2 | 16.4 | 17.9 | 16.1 | 4.6 | 11.1 | 8.5 |
| Duration of conventional therapy, days | |||||||||||||
| 0 | 26.6 | 23.1 | 28.9 | 28.3 | 22.0 | 28.7 | 36.8 | 25.5 | 23.2 | 26.2 | 25.0 | 25.9 | 29.8 |
| 1-30 | 11.3 | 12.1 | 9.8 | 9.6 | 13.4 | 10.7 | 14.6 | 0.0 | 16.1 | 8.7 | 20.5 | 7.4 | 14.9 |
| 31-60 | 13.6 | 12.9 | 11.3 | 11.7 | 18.7 | 13.3 | 14.6 | 14.6 | 10.7 | 12.4 | 22.7 | 22.2 | 8.5 |
| 61-90 | 9.7 | 9.6 | 8.8 | 10.3 | 9.5 | 8.8 | 10.8 | 20.0 | 10.7 | 8.3 | 6.8 | 7.4 | 19.2 |
| ≥91 | 38.9 | 42.4 | 41.2 | 40.1 | 36.3 | 38.5 | 23.2 | 40.0 | 39.3 | 44.5 | 25.0 | 37.0 | 27.7 |
Values are mean (SD) or %.
Abbreviations: ADA, adalimumab; CCI, Charlson Comorbidity Index; IFX, infliximab; UST, ustekinumab; VDZ, vedolizumab.
aThe 5 most prevalent conditions in the total Crohn’s disease cohort.